<DOC>
	<DOCNO>NCT00090766</DOCNO>
	<brief_summary>This study ass safety pharmacokinetics Valcyte syrup pediatric solid organ transplant recipient . The anticipated time study treatment 3-12 month target sample size le 100 individual .</brief_summary>
	<brief_title>A Study Valcyte ( Valganciclovir ) Syrup Formulation Pediatric Solid Organ Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>patient 3 month 16 year age ; first solid organ transplant ( eg , kidney , liver , heart ) ; able tolerate oral medication ; female childbearing potential must agree utilize effective method contraception throughout study 90 day follow discontinuation study drug ; patient risk develop CMV disease ( transplant recipient DR CMV ) . patient previously participate study ; patient participate another clinical trial ( except approval Sponsor ) ; severe , uncontrolled diarrhea ( 5 watery stool per day ) ; pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>